Abstract: A process for the preparation of derivatives of halo-but-2-enoic acids and esters high in 2-ene content, several of which are novel. The esters and their derivatives are useful as promoters for the polymerization of ethylene or the copolymerization of ethylene with .alpha.-olefins and, optionally, nonconjugated polyenes. The promoters can also be combined with transition metal compounds, e.g., vanadium, to form combination promoter-catalyst compounds.

Abstract: Organometallic compounds useful for forming aluminum films by chemical vapor deposition are disclosed. Also disclosed are methods of preparing the organimetallic compounds and methods of forming aluminum films.

Abstract: Complexes of a selected class of chiral ligands with molybdenum, tungsten or chromium, preferably molybdenum, are effective as catalysts in highly enantioselective and regioselective alkylation of allylic substrates. Such compositions provide a versatile and low-cost alternative to existing catalysts.

Abstract: Organometallic precursor compounds useful for forming aluminum films by chemical vapor deposition are disclosed. Also disclosed are methods of preparing the organometallic precursor compounds and methods of forming aluminum films.

Abstract: This invention provides novel antitumor demethylcantharidin platinum complexes. This invention also provides a composition comprising at least one of said demethylcantharidin platinum complexes and a suitable carrier. This invention provides a pharmaceutical composition comprising effective amount of at least one of the said demethylcantharidin platinum complexes and a pharmaceutically acceptable carrier. This invention provides a method of inhibiting the growth of tumorous cells comprising contacting the cells with an amount of said demethylcantharidin platinum complex effective to inhibit the growth of said tumorous cells. This invention provides a method of inhibiting the growth of tumorous cells in a subject comprising administering to the subject with an amount of the said demethylcantharidin platinum complexes effective to inhibit the growth of said tumorous cells in the subject. Finally, this invention provides methods for producing said demethylcantharidin platinum complexes.

Abstract: Disclosed herein is a process for the polymerization of ethylene, norbornenes and styrenes, by contacting in solution a selected nickel compound and a selected compound which is or can coordinated to the nickel with the olefin(s). The polymers produced are useful for films and molding resins.

Abstract: This invention is concerned with a ruthenium-iodo-optically active bidentate phosphine complex of the formula (I):[Ru--(I).sub.q --(T.sup.1).sub.n (SOL).sub.r (L)].sub.m (T.sup.2).sub.p (I).sub.s (I)wherein T.sup.1 represents a carboxylic acid anion, SOL represents a polar solvent, L represents an optically active bidentate phosphine ligand, T.sup.2 represents an anion different from halogen atom anions and carboxylic acid anions, n denotes 0 or 1, r denotes 0, 3 or 4, m denotes 1 or 2, q denotes 0 or 1, or where m is 2, q may represent 1 or 1.5, p denotes 0 or 1, and s denotes 0, 1 or 2 is prepared. Said phosphine complex is usefull as an efficient catalyst for asymmetrically hydrogenating 4-methylene-2-oxetanone into optically active 4-methyl-2-oxetanone.

Abstract: Platinum (IV) complexes for oral administration represented by the structural formula ##STR1## where A--A is a symmetrical diamine that can chelate to platinum and is selected from the group consisting of ethylene diamine, t(.+-.)-1,2-diaminocyclohexane, 2,2-dimethyl-1,3-propanediamine, cyclohexane-1,1-dimethaneamine and tetrahydro-4H-pyran-4,4-dimethaneamine; and R is propionyl, butyryl or valeryl. These complexes are useful in the treatment of cancer.

Abstract: Optically active diphosphine ligands of the formula I, ##STR1## where: R.sup.1 is hydrogen, C.sub.1 -C.sub.10 -acyl, C.sub.1 -C.sub.10 -alkyl, C.sub.2 -C.sub.10 -alkenyl, each of which may be linear or branched, aryl, arylalkyl, in which the ring systems may be substituted in each case, ##STR2## R.sup.2, R.sup.3 independently of one another are C.sub.1 -C.sub.10 -alkyl, which may be linear or branched, aryl, arylalkyl, in which the ring systems may be substituted in each case,R.sup.4, R.sup.5, R.sup.6 independently of one another are C.sub.1 -C.sub.10 -alkyl, which may be linear or branched, aryl, arylalkyl, in which the ring systems may be substituted in each case.

Abstract: A compound of the formula (I): ##STR1## or pharmaceutical acceptable salts thereof wherein X is NR.sub.1, S(O).sub.g, or O; R.sub.1 is H, C.sub.1-6 alkyl optionally substituted with one or more OH, CN, or halo, or R.sub.1 is --(CH.sub.2).sub.h -- aryl, --COR.sub.1--1, --COOR.sub.1-2, --CO--(CH.sub.2).sub.h --COR.sub.1--1, C.sub.1-6 alkyl sulfonyl, --SO.sub.2 --(CH.sub.2).sub.h --aryl, or --(CO).sub.i --Het; R.sub.2 is H, C.sub.1-6 alkyl, --(CH.sub.2).sub.h --aryl, or halo; R.sub.3 and R.sub.4 are the same or different and are H or halo; R.sub.5 is H, C.sub.1-12 alkyl optionally substituted with one or more halo, C.sub.3-12 cycloalkyl, C.sub.1-6 alkoxy. The compounds are useful antimicrobial agents.

Abstract: The hydrolyzable and polymerizable silanes have the formula I, ##STR1## wherein X is hydrogen, a halogen, a hydroxy, an alkoxy group, an acyloxy oup, an alkylcarbonyl group, an alkoxycarbonyl group or --NR.sup.2.sub.2 group; wherein R.sup.

Abstract: The present invention provides a novel optically active bidentate phosphine ligand palladium complex of formula (I) or (II) which can be used for the preparation of optically active .beta.-hydroxyketones: ##STR1## ?wherein Y.sup.- represents an anion pair which may form salt; X represents ##STR2## {wherein R.sup.1 represents hydrogen atom, C.sub.1-6 alkyl group, C.sub.1-6 alkoxyl group, cyano group, nitro group, halogen atom or phenyl group, etc.; m represents 1 or 2; when m is 2, two R.sup.1 s may be same or different}; andA and B each independently represents phenyl group or cyclohexyl group {said phenyl group and cyclohexyl group each is unsubstituted or substituted by R.sup.2 (R.sup.2 has the same meaning as defined in R.sup.1)}).

Abstract: The present invention provides several methods of synthesis and separation in which organic/fluorous phase separation techniques are used to effect separations. The present invention also provides novel compositions of matter comprising fluorous Si, Sn and Ge compounds.

Abstract: A metalorganic complex of the formula:MA.sub.y Xwherein:M is a y-valent metal;A is a monodentate or multidentate organic ligand coordinated to M which allows complexing of MA.sub.y with X;y is an integer having a value of 2, 3 or 4; each of the A ligands may be the same or different; andX is a monodentate or multidentate ligand coordinated to M and containing one or more atoms independently selected from the group consisting of atoms of the elements C, N, H, S, O and F.The metal M may be selected from the group consisting of Cu, Ba, Sr, La, Nd, Ce, Pr, Sm, Eu, Th, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Bi, Tl, Y, Pb, Ni, Pd, Pt, Al, Ga, In, Ag, Au, Co, Rh, Ir, Fe, Ru, Sn, Li, Na, K, Rb, Cs, Ca, Mg, Ti, Zr, Hf, V, Nb, Ta, Cr, Mo, and W. A may be selected from the group consisting of .beta.-diketonates and their sulfur and nitrogen analogs, .beta.-ketoesters and their sulfur and nitrogen analogs, cyclopentadienyls, alkyls, perfluoroalkyls, alkoxides, perfluoroalkoxides, and Schiff bases.

Abstract: A process for preparing metallocene complexes of the general ##STR1## in which the substituents have the following meanings:M is titanium, zirconium, hafnium, vanadium, niobium or tantalum,X is fluorine, chlorine, bromine, iodine, hydrogen, C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.15 -aryl or --OR.sup.5,where R.sup.5 is C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.15 -aryl, alkylaryl, aryl-alkyl, fluoroalkyl or fluoroaryl with, in each case, 1 to 10 carbon atoms in the alkyl radical and 6 to 20 carbon atoms in the aryl radical,R.sup.1 to R.sup.4 and R.sup.6 to R.sup.9 are hydrogen, C.sub.1 -C.sub.10 -alkyl, 5- to 7-membered cycloalkyl which can in turn carry C.sub.1 -C.sub.10 -alkyls as substituents, or C.sub.6 -C.sub.15 -aryl or aryl-alkyl, it also being possible where appropriate for two adjacent radicals together to be cyclic groups having 4 to 15 carbon atoms, or Si(R.sup.10).sub.3 withR.sup.10 being C.sub.1 -C.sub.10 -alkyl, C.sub.6 -C.sub.15 -aryl or C.sub.3 -C.sub.

Abstract: The present invention provides a method for carrying out a chemical reaction comprising the steps of forming an organic/fluorous solubilizing liquid phase comprising a solvent system. The solvent system is selected or adapted to substantially solubilize a fluorous reaction component or components (that is, a fluorous reagent, a fluorous catalyst and/or a fluorous reactant). The "fluorous reaction component" is functionalized to comprise at least one fluorous moiety having the formula -(R).sub.d (Rf).sub.e. (Rf).sub.e is at least one fluorous group and e is a whole number. (R).sub.d is an organic (for example, hydrocarbon) spacer group, which may be present or absent, and d is an integer equal to at least zero. The solvent system is also adapted to substantially solubilize an organic reaction component or components. After the reaction occurs in the organic/fluorous solubilizing liquid phase, a phase separation into at least a fluorous phase and an organic phase is effected.

Abstract: A compound, composition, and method for controlling Take-all disease of plants by applying a fungicide of the formula: ##STR1## wherein Z.sub.1 and Z.sub.2 are carbons of a furan ring; A is selected from the group consisting of --C(X)-amine wherein the amine is substituted with a first and a second amine substituent or with an alkylaminocarbonyl and a hydrogen, --C(O)--SR.sub.3 ; --NH--C(X)R.sub.4, and --C(.dbd.NR.sub.3)--XR.sub.7 ;B is --W.sub.m --Q(R.sub.2).sub.3 or selected from o-tolyl, 1-naphthyl, 2-naphthyl, and 9-phenanthryl, each optionally substituted with halogen or R.sub.4 ; Q is C, Si, Ge, or Sn; W is --C(R.sub.3).sub.p H.sub.(2-p) --; or when Q is C, W may also be selected from --N(R.sub.3).sub.m H.sub.(1-m) --, --S(O).sub.p --, and --O--; X is O or S; n is 0, 1, or 2; m is 0 or 1; p is 0, 1, or 2;wherein two R.sub.

Abstract: Fluoroaluminate compounds of formula M.sup.+n (AlF.sub.4).sub.n.sup.- wherein n is 1 to 3 and M.sup.+n is N(R.sub.2).sub.4, P(R.sub.2).sub.4, As(R.sub.2).sub.4, HN(R.sub.2).sub.3, H.sub.2 N(R.sub.2).sub.2, H.sub.3 N(R.sub.2), (R.sub.2).sub.3 P.dbd.N.dbd.P(R.sub.2).sub.3, S?N(R.sub.2).sub.2 !.sub.3, ##STR1## (R).sub.2 N--(C(R).sub.2).sub.k --N(R).sub.3, and ZH.sub.m.sup.+m wherein Z is a base capable of accepting m protons, and various cyclic and aryl groups are disclosed as well as processes for their preparation.

Abstract: The invention provides lanthanide chelates capable of intense luminescence. The celates comprise a lanthanide chelator covalently joined to a coumarin-like or quinolone-like sensitizer. Exemplary sensitzers include 2- or 4-quinolones, 2- or 4-coumarins, or derivatives thereof e.g. carbostyril 124 (7-amino-4-methyl-2-quinolone), coumarin 120 (7-amino-4-methyl-2-coumarin), coumarin 124 (7-amino-4-(trifluoromethyl)-2-coumarin), aminomethyltrimethylpsoralen, etc.The chelates form high affinity complexes with lanthanides, such as terbium or europium, through chelator groups, such as DTPA. The chelates may be coupled to a wide variety of compounds to create specific labels, probes, diagnostic and/or therapeutic reagents, etc. The chelates find particular use in resonance energy transfer between chelate-lanthanide complexes and another luminescent agent, often a fluorescent non-metal based resonance energy acceptor.

Abstract: A compound of formula (I): ##STR1## n which M is a transition metal ion; A is a counter-ion if required;r, s and t are independently 0 to 3 such that r+s+t is in the range of 1 to 3;R.sup.a, R.sup.b, R.sup.c are each independently hydrogen or CH.sub.2 OR' where R' is hydrogen or an organic group;B and E are independently oxygen, CH.sub.2, NR.sup.d in which R.sup.d is alkyl, hydrogen, alkylcarbonyl, or arylcarbonyl or SO.sub.n where n is 0 or an integer 1 or 2, with the proviso that B and E are not simultaneously CH.sub.2 and that when B is oxygen, NR.sup.d or SO.sub.n, then r cannot be 0, and when E is oxygen, NR.sup.d or SO.sub.n, then t cannot be 0;R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are independently hydrogen, alkyl or alkoxy.

Abstract: Enantioselective hydroformylation of vinyl compounds using a catalyst composition of a chiral carbohydrate phosphorous ligand with a Rh, Pt, Co or Ir metal, to produce chiral 2-substituted propanals, wherein the phosphorous of the ligand is substituted with electron withdrawing groups.

Abstract: Organosilicon compounds having Si-bonded hydrogen atoms are reacted with organic compounds having aliphatic multiple bonds in the presence of triazene oxide-transition metal complexes. The triazene oxide-transition metal complexes are activated by heating at temperatures of from 50.degree. C. to 250.degree. C. and/or by irradiation with light.

Abstract: A process and catalyst composition are provided for the highly efficient enantioselective hydrogenation of dehydroamino acid derivatives. The catalyst composition comprises rhodium or iridium and a diphosphinite carbohydrate ligand, wherein the phosphorous atoms are attached to aromatic groups substituted with electron-donating substituents. Also provided is a means to selectively produce .alpha. amino acids in either the L or the D form, based upon use of a sugar in the ligand with phosphinites attached in an absolute Right-Left or Left-Right configuration, respectively.

Abstract: The invention relates to salts formed between ranitidine and a complex of zinc with a carboxylic acid selected from tartaric acid, citric acid and alkyl citric acids, and to solvates of such salts. The salts and solvates thereof are useful in the treatment of gastro-intestinal disorders, such as peptic ulcer disease and non-ulcer dyspepsia.

Abstract: Disclosed herein are novel platinum(II) complexes having a potent anti-tumor activity which are represented by the formula (1), ##STR1## wherein R.sub.1 and R.sub.2, which may be the same or different, are a hydrogen atom or a C.sub.1-4 alkyl group, respectively, or jointly form a cycloalkane group together with the carbon atom attached thereto; two Xs jointly form a group represented by formula (a) or (b) wherein, R.sub.3 is a hydrogen atom or a methyl group; R.sub.4 and R.sub.5, which may be the same or different, are a hydrogen atom or a C.sub.1-4 alkyl group, respectively, or jointly form a cyclobutane together with the carbon thereto; and the absolute configurations at the respective chiral centers in the 4,5-bis(aminomethyl)-1,3-dioxolane moiety are (4R,5R) or (4S,5S); processes for the preparing the same; and their use for treating animal or human cancer.

Abstract: Novel trisstannoxanes are prepared by the reaction of a dialkyltin oxide with a trihydroxy compound such as 1,1,1-tris(hydroxymethyl)propane. They may be employed as catalysts for the preparation of branched polyesters from macrocyclic polyester oligomers. They are less susceptible than previously known catalysts to the presence of acidic impurities in the oligomer compositions.

Abstract: TiCl.sub.3 coordination complexes with ethers are prepared by adding TiCl.sub.3.1/3AlCl.sub.3 to an ether solvent so as to form a solid TiCl.sub.3 -ether coordination complex in said solvent.

Abstract: Novel 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracyclines having activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines are disclosed. Also disclosed are intermediates and methods for making the novel compounds of the present invention.

Abstract: Water-soluble complexes having the formula: ##STR1## and stereoisomers thereof, where Z.sup.1 and Z.sup.2 are halogens, and X.sup.1 and X.sup.2 are selected from the group consisting of sulfate, phosphate, nitrate, and monocarboxylate, or are jointly dicarboxylate, have been found to have desirable antitumor activity, as well as relatively low levels of toxicity.

Abstract: Titanocenes of the formula I ##STR1## in which R.sup.1 are cyclopentadienyl.sup..crclbar. groups and R.sup.2 and R.sup.3 are aromatic radicals which are substituted in both ortho-positions by fluorine and, in addition, are substituted by an acyloxy group are suitable as photoinitiators for the photopolymerization of ethylenically unsaturated compounds.

Abstract: A novel platinum (II) complex represented by the following formula (A): ##STR1## wherein R.sub.1 represents C.sub.1 -C.sub.5 lower hydrocarbon group, R.sub.2 and R.sub.3 represents hydrogen atom or C.sub.1 -C.sub.3 lower hydrocarbon group, the configuration of 1,2-diaminocyclohexane being cis, trans-l- or trans-d-. Since the platinum (II) complex has a strong anti-tumor activity and its toxicity is low, it is useful as an agent for treating malignant tumor.

Abstract: Volatile organic barium, strontium and calcium compounds, which consist of the complex of a barium-, strontium- or calcium-.beta. diketonate and one or more coordinating ligands, characterized in that at least one coordinating ligand of the barium or strontium compound is formed by a neutral oxygen or a neutral nitrogen donor ligand, or one of the coordinating ligands of the calcium compound is formed by a neutral oxygen donor ligand.

Abstract: New complexes of general formula (I) in whichR.sub.1 and R.sub.2 together form a saturated or unsaturated polycyclic carbocyclic radical containing 7 to 12 carbon atoms, or a saturated or partially saturated mono-, bi- or tricyclic heterocyclic radical containing 5 to 11 chain members and a hetero-atom chosen from oxygen, sulphur or nitrogen, which latter atom can optionally be substituted by an alkoxycarbonyl radical, and,X.sub.1 and X.sub.2 represent chlorine atoms or together formeither a radical of structure: ##STR1## in which n is 0 to 2 and R.sub.6 and R.sub.7, which are identical or different, are hydrogen atoms or, when n=1, can be alkyl radicals or form, together with the carbon atom to which they are attached, a cyclobutyl radical,or a radical of structure: ##STR2## in which n, R.sub.6 and R.sub.7 are defined as above, or their salts where such exist, and their hydrates, their preparation and the pharmaceutical compositions which contain them.

Abstract: Titanocenes of the formula I ##STR1## in which R.sup.1 are cyclopentadienyl.sup..crclbar. groups and R.sup.2 and R.sup.3 are aromatic radicals which are substituted in both ortho-positions by fluorine and, in addition, are substituted by an acyloxy group are suitable as photoinitiators for the photopolymerization of ethylenically unsaturated compounds.

Abstract: Compounds of general formula I or Ia ##STR1## or mixtures thereof, wherein the groups P-L-P are a ligand from the group comprising diphosphine and diphosphinite, in which the secondary phosphine groups or phosphinite groups P are coupled via 2 to 4 C atoms, and which form a 5-, 6- or 7-membered ring with the Ir atoms, X, X.sup.1, X.sup.2, X.sup.3, X.sup.4, X.sup.5 and X.sup.6 independently of the others are Cl, Br or I, or X.sup.1 and X.sup.6 and H and X.sup.2, X.sup.3, X.sup.4 and X.sup.5 independently of the others are Cl, Br or I, or X.sup.1 and X.sup.5 and H and X.sup.2, X.sup.3, X.sup.4 and X.sup.6 independently of the others are Cl, Br or I, and M.sup..sym. is an alkali metal cation or quaternary ammonium. The compounds are suitable as homogeneous catalysts for the (preferably) asymmetric hydrogenation of N-substituted imines to secondary amines.

Abstract: A process is provided herein for preparing an organo-substituted sodium aluminum hydride by reacting sodium, aluminum, an organic compound of specific structure containing a hydroxyl group and hydrogen.In such process, an aluminum alloy is used as the aluminum.

Abstract: This invention relates to the novel processes for the preparation of a 16-methoxy-16-methyl prostaglandin E.sub.1 derivative and to the novel intermediates useful therefor.

Abstract: A novel optically active allyl alcohol derivative represented by the following general formulae (I), (II), (III) and (IV): ##STR1## The novel optically active allyl alcohol can be used effectively for producing leucotrienes B.sub.4 by the process of reacting an optically active halogen substituted allyl alcohol and a novel optically active acetylene-substituted allyl alcohol.

Abstract: Compounds of the formula I ##STR1## in which Me is Ti, Zr or Hf, R.sub.1 is a group transferable to aldehyde, keto or imine groups, for example methyl, allyl, vinyl or the radical of an enol or enamine, R.sub.2 is, for example, cyclopentadienyl, R.sub.3 and R.sub.4 are, for example, H or alkyl, R.sub.5 is, for example, phenyl and the C(1) and C(2) atoms are chiral and have predominantly one configuration, are suitable for use as chiral reactants for aldehydes, ketones and imines for the preparation of both enantiomers of secondary or tertiary alcohols or tertiary amines.

Abstract: Furan derivatives of the general formula I ##STR1## where: X is an anion of pharmaceutically acceptable acids;a is an integer from 1 to 5;b is an integer from 1 to 7;c is zero or an integer from 1 to 4; andd is 2a-c, for anions of monovalent acids, is a-c, for anions of divalent acids, and is zero or 2, when c is zero,are described as having notable antiulcer properties.A process for the preparation of said furan derivatives based on reacting N,N-dimethyl-5-(2-(1-methylamino-2-nitrovinylamino)ethylthiomethyl)furfury lamine and an X anion-containing zinc compound or an organozinc is also disclosed.

Abstract: Platinum complexes of the general formula I[(R.sup.1 NH.sub.2).sub.n Pt].sub.q Y.sub.m X.sub.p (I)in which Y is a phosphonic acid ligand, and the preparation thereof, are described. The platinum complexes are suitable as active substances in pharmaceuticals, in particular for controlling cancers.

Abstract: The present invention comprises a water-soluble square-planar cis-platinum(II) four-coordinate complex having the formula:trans-R,R-DACH Pt(II) X.sub.2ortrans-R,R-DACH Pt(II) Ywherein X is a monovalvent cation, two of which are present, selected from the group consisting of cyclopropanecarboxylato, shikimato, saccharatolactone, galacturonato and N,N-dimethyglycinato; wherein Y is a divalent cation selected from the group consisting of citraconato, 1,1-cyclobutanedicarboxylato, 1,1-cyclopropanedicarboxylato, isocitratolactone and Z-iminodiacetato where Z is bound to the nitrogen and is ethyl, propyl, Isopropyl, n-butyl, sec-butyl, ter-butyl, n-amyl, isoamyl or OH.In one preferred aspect the water-soluble square-planar cis-platinum(II) four-coordinate complex has the formula:trans-R,R-DACH Pt(II) X.sub.2wherein X is a monovalent cation. Two X substituents are present in the platinum complex.

Abstract: The invention relates to salts formed between ranitidine and a complex of bismuth with a carboxylic acid, and solvates of such salts. Examples of suitable carboxylic acids are citric acid, tartaric acid and agaricic acid.The salts are useful in the treatment of gastrointestinal disorders, particularly gastroduodenal conditions. The salts show the antisecretory activity associated with ranitidine together with antibacterial activity against Campylobacter pylori and they also possess cytoprotective properties.

Abstract: This disclosure sets forth a novel process for producing cisplatin analogs which possess antitumor activity.

Abstract: This disclosure sets forth a novel process for producing cisplatin analogs which possess antitumor activity.

Abstract: Organic platinum complexes active as anti-tumor agents in warm-blooded animals, and methods for synthesis of same, are described.

Abstract: Antimony trioxide is reached with an organic mercaptan R.sup.1 --SH or R.sup.2 --OCO--(CH.sub.2).sub.n --SH (where R.sup.1 is an alkyl, alkenyl, aryl, aralkyl, cycloalkyl or heterocyclic group having from 1 to 18 carbon atoms, which optionally has sulfide bond or ether bond or a hydroxyl or carboxyl group as a substituent, R.sup.2 is a hydrogen atom or an alkyl, alkenyl, aryol, aralkyl, cycloalkyl or heterochclic group having from 1 to 18 carbon atoms, which optionally has sulfide bond or ether bond or a hydroxyl or carboxyl group as a substituent, and n is 1 to 3) in the presence of a lower aliphatic carboxylic acid to give an antimony mercaptide Sb(--SR.sup.1).sub.3 or Sb(--S--(CH.sub.2).sub.n --COOR.sup.2).sub.3 of high purity with high yield. The products are excellent in the time-dependent stability and the effect as a passivator for catalysts for catalytic cracking of hydrocarbons.

Abstract: Pigments of the general formulaF.multidot.Het (I)where F is the cation of a cationic dye which has an absorption maximum at >700 nm and may or may not contain anionic groups and Het is an anion of a heteropolyacid based on tungsten, molybdenum, vanadium or a mixture of these with phosphorus, silicon, cobalt, aluminum, manganese, chromium, nickel or a mixture of these or a copper(I)-hexacyanoferrate(II) anion, are superior to the known IR dyes in terms of thermal stability and photostability, and give optical recording media having superior properties, such as a high signal/noise ratio.

Abstract: Complexes of the general formula I[R.sup.1 (CH.sub.2).sub.m C(O)CR.sup.3 C(O)R.sup.2 ].sub.2+n MX.sub.2-n (I)wherein M denotes tin, titanium, zirconium or hafnium, R.sup.1 denotes hydrogen or a phenyl radical, it being possible for the phenyl radical to be monosubstituted or polysubstituted by fluorine, chlorine, bromine, nitro, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or trifluoromethyl, R.sup.2 denotes methyl or R.sup.1, with the exception of hydrogen, R.sup.3 denotes hydrogen or chlorine, X denotes fluorine, chlorine or bromine, but not fluorine if M denotes zirconium or hafnium, m denotes the number 1 or 0, or, if R.sup.1 denotes hydrogen, the number 1 and n denotes the number 0, or, if M denotes zirconium or hafnium, the number 1 or 0, exhibit a cytostatic activity which is comparable to that of cisplatin and are less toxic than cisplatin. They are suitable for the produduction of medicaments having an anti-neoplastic action.

Abstract: There are described platinum-polyhydroxylated amine compounds which exhibit anti-tumor activity in mammalian species. The products are highly soluble in aqueous solutions and they may be administered either orally or in parenteral form.